Ashley Kimmet, LCPC Counselor - Professional Medicare: Medicare Enrolled Practice Location: 802 2nd St Se, Cut Bank, MT 59427 Phone: 406-873-2251 Fax: 406-873-3118 |
Jeannine R Willison, LAC Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 1210 E Main St, Cut Bank, MT 59427 Phone: 406-873-2155 |
Ms. Kathleen Egan Egan Broere, LCPC, NBCC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 60 Loring Rd., Cut Bank, MT 59427 Phone: 406-336-3021 |
David Stanley Ketchell, LCPC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 519 E Main St, Cut Bank, MT 59427 Phone: 406-873-5670 Fax: 406-873-2256 |
Debora O'brien, MS LCPC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 706 2nd St Se, Cut Bank, MT 59427 Phone: 406-873-4174 Fax: 406-873-4360 |
Glenda R Comes At Night, LAC Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 1210 E Main St, Cut Bank, MT 59427 Phone: 406-873-2155 |
Virginia Gosney, LAC Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 1210 E Main St, Cut Bank, MT 59427 Phone: 406-873-2155 Fax: 406-873-2155 |
News Archive
Heavy smoking in midlife is associated with a 157 percent increased risk of developing Alzheimer's disease and a 172 percent increased risk of developing vascular dementia, according to a Kaiser Permanente study published in the Archives of Internal Medicine.
Long the domain of philosophy and religion, free will has also been defined by scientists as a combination of two cognitive processes - the desire to act (or volition) and the sense of responsibility for our actions (or agency.)
Mice that sleep fitfully could help researchers unravel the mystery of insomnia. Researchers at Washington University School of Medicine in St. Louis studied mice genetically modified to mimic the genetic disease neurofibromatosis type 1, which is associated with sleep problems.
Cell Therapeutics, Inc. today announced that the North Central Cancer Treatment Group ("NCCTG") plans to conduct a Phase II study of brostallicin in combination with cisplatin in patients with metastatic triple-negative breast ("mTNBC") cancer, defined by tumors lacking expression of estrogen, progesterone receptors and without over-expression of HER2. Additionally, the majority of breast cancers that are associated with the susceptibility mutation (BRCA1) are of the triple-negative type.
› Verified 6 days ago